Compare Stocks: NVO, JNJ, MRK, and NVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$271.58 +0.1%	$265.53	$177.32 ▼ $281.07	$654.48B	0.24	6.05 million shs	4.06 million shs
MRK Merck & Co., Inc.	$148.75 0.0%	$140.89	$77.69 ▼ $156.92	$366.99B	0.21	9.47 million shs	8.28 million shs
NVO Novo Nordisk A/S	$38.81 +0.0%	$45.72	$35.12 ▼ $64.16	$173.30B	0.74	12.76 million shs	9.92 million shs
NVS Novartis	$145.49 +0.0%	$151.67	$121.57 ▼ $170.46	$277.62B	0.45	2.55 million shs	1.17 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+0.60%	+1.22%	+5.17%	+51.14%
MRK Merck & Co., Inc.	0.00%	+1.52%	+0.30%	+15.23%	+89.47%
NVO Novo Nordisk A/S	0.00%	-10.23%	-14.87%	-19.74%	-30.20%
NVS Novartis	0.00%	+3.57%	-5.37%	-7.66%	+17.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$271.58 +0.1%	$265.53	$177.32 ▼ $281.07	$654.48B	0.24	6.05 million shs	4.06 million shs
MRK Merck & Co., Inc.	$148.75 0.0%	$140.89	$77.69 ▼ $156.92	$366.99B	0.21	9.47 million shs	8.28 million shs
NVO Novo Nordisk A/S	$38.81 +0.0%	$45.72	$35.12 ▼ $64.16	$173.30B	0.74	12.76 million shs	9.92 million shs
NVS Novartis	$145.49 +0.0%	$151.67	$121.57 ▼ $170.46	$277.62B	0.45	2.55 million shs	1.17 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+0.60%	+1.22%	+5.17%	+51.14%
MRK Merck & Co., Inc.	0.00%	+1.52%	+0.30%	+15.23%	+89.47%
NVO Novo Nordisk A/S	0.00%	-10.23%	-14.87%	-19.74%	-30.20%
NVS Novartis	0.00%	+3.57%	-5.37%	-7.66%	+17.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$274.13	0.94% Upside
MRK Merck & Co., Inc.	2.71	Moderate Buy	$154.24	3.69% Upside
NVO Novo Nordisk A/S	2.11	Hold	$64.94	67.31% Upside
NVS Novartis	2.38	Hold	$153.00	5.16% Upside

Current Analyst Ratings Breakdown

Latest NVO, JNJ, MRK, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	NVO Novo Nordisk A/S	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/10/2026	JNJ Johnson & Johnson	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $320.00
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$123.00 ➝ $136.00
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$123.00 ➝ $136.00
9/10/2026	MRK Merck & Co., Inc.	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$150.00 ➝ $172.00
9/9/2026	MRK Merck & Co., Inc.	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$127.00 ➝ $161.00
9/8/2026	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
9/8/2026	NVS Novartis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform
9/8/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$146.00 ➝ $170.00
9/4/2026	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$150.00 ➝ $170.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$97.93B	6.68	$14.14 per share	19.21	$33.85 per share	8.02
MRK Merck & Co., Inc.	$65.01B	5.65	$11.42 per share	13.02	$21.22 per share	7.01
NVO Novo Nordisk A/S	$46.80B	3.70	$4.69 per share	8.28	$6.58 per share	5.90
NVS Novartis	$54.53B	5.09	$10.74 per share	13.55	$22.04 per share	6.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	31.47	21.17	2.59	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	119.00	15.48	6.48	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	9.49	11.35	1.27	35.36%	58.61%	20.91%	11/4/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	21.94	14.82	2.81	23.29%	38.56%	14.47%	10/27/2026 (Estimated)

Latest NVO, JNJ, MRK, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/13/2026	Q3 2026	JNJ Johnson & Johnson	$2.85	N/A	N/A	N/A	$25.35 billion	N/A
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	1.97%	+5.25%	62.11%	64 Years
MRK Merck & Co., Inc.	$3.40	2.29%	+5.75%	272.00%	14 Years
NVO Novo Nordisk A/S	$0.82	2.11%	+21.74%	20.05%	N/A
NVS Novartis	$3.08	2.12%	+5.28%	46.46%	N/A

Latest NVO, JNJ, MRK, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.36%	9/15/2026	9/15/2026	10/7/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
MRK Merck & Co., Inc.	1.22	1.32	1.10
NVO Novo Nordisk A/S	0.55	0.87	0.66
NVS Novartis	0.89	0.86	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.17%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

NVO, JNJ, MRK, and NVS Headlines

Recent News About These Companies

Zacks Research Brokers Boost Earnings Estimates for Novartis

11 minutes ago | americanbankingnews.com

Novartis Stock Earnings Estimates Raised by Zacks Research

13 minutes ago | marketbeat.com

Novartis AG $NVS Shares Sold by State Street Corp

September 26 at 3:36 AM | marketbeat.com

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

September 26 at 3:15 AM | finance.yahoo.com

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

September 25 at 10:11 PM | insidermonkey.com

FY2027 EPS Estimates for Novartis Lifted by Erste Group Bank

September 25 at 1:13 AM | americanbankingnews.com

Envestnet Asset Management Inc. Acquires 19,595 Shares of Novartis AG $NVS

September 24, 2026 | marketbeat.com

QRG Capital Management Inc. Raises Stock Position in Novartis AG $NVS

September 23, 2026 | marketbeat.com

Novartis stock gains 0.62 percent at the close

September 23, 2026 | ad-hoc-news.deA

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

September 23, 2026 | zacks.com

FY2027 EPS Estimates for Novartis Raised by Erste Group Bank

September 23, 2026 | marketbeat.com

Novartis stock ends the day at USD 141.43 after the close

September 23, 2026 | ad-hoc-news.deA

BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln

September 22, 2026 | rttnews.com

Erste Group Bank Forecasts Increased Earnings for Novartis

September 22, 2026 | marketbeat.com

Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial

September 21, 2026 | insidermonkey.com

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

September 21, 2026 | zacks.com

Novartis' Pipeline In Focus After A Series Of Clinical Setbacks

September 21, 2026 | rttnews.com

EMA panel backs Novartis Cosentyx for rheumatic condition in EU

September 18, 2026 | streetinsider.com

Novartis Gains Positive CHMP Opinion For Cosentyx In Polymyalgia Rheumatica; EC Decision By Nov '26

September 18, 2026 | rttnews.com

Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years

September 17, 2026 | finance.yahoo.com

Novartis AG (NYSE:NVS) Receives $153.00 Average Price Target from Brokerages

September 17, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, JNJ, MRK, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

$271.58 +0.36 (+0.13%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$270.63 -0.95 (-0.35%)

As of 09/25/2026 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$148.75 -0.03 (-0.02%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$148.50 -0.25 (-0.16%)

As of 09/25/2026 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$38.81 +0.01 (+0.03%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$38.80 -0.02 (-0.04%)

As of 09/25/2026 08:00 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$145.49 +0.03 (+0.02%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$144.92 -0.58 (-0.40%)

As of 09/25/2026 07:57 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, JNJ, MRK, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, JNJ, MRK, and NVS Earnings

Compare Dividends

Latest NVO, JNJ, MRK, and NVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, JNJ, MRK, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, JNJ, MRK, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools